Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-blind, Placebo-controlledTrial of Golimumab, a Fully Human Anti-TNFa MonoclonalAntibody, Administered Subcutaneously, in Methotrexate-naive Subjects With Active Rheumatoid Arthritis
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of golimumab, alone or in combination with methotrexate, as compared to methotrexate alone in rheumatoid arthritis subjects who have not been previously treated with methotrexate.


Options:
A: Arm Label: Abatacept + Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Abatacept, Drug: Methotrexate | Arm Label: Placebo + Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Placebo | Arm Label: Abatacept + Methotrexate Open Label; Type: EXPERIMENTAL; Interventions: Drug: Abatacept, Drug: Methotrexate | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept + Methotrexate, Abatacept + Methotrexate Open Label | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Abatacept + Methotrexate, Abatacept + Methotrexate Open Label, Placebo + Methotrexate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Methotrexate
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Methotrexate | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 3
C: Arm Label: Group 1: Placebo + Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Placebo injections, Drug: Methotrexate capsules, Biological: Golimumab 50 mg injections, Biological: Golimumab 100 mg injections | Arm Label: Group 2: Golimumab 100 mg + Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo capsules, Drug: Methotrexate capsules, Biological: Golimumab 50 mg injections, Biological: Golimumab 100 mg injections | Arm Label: Group 3: Golimumab 50 mg + Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Methotrexate capsules, Biological: Golimumab 50 mg injections, Biological: Golimumab 100 mg injections | Arm Label: Group 4: Golimumab 100 mg + Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Methotrexate capsules, Biological: Golimumab 50 mg injections, Biological: Golimumab 100 mg injections | Intervention Type: DRUG; Name: Placebo injections; Assigned to Arm(s): Group 1: Placebo + Methotrexate | Intervention Type: DRUG; Name: Placebo capsules; Assigned to Arm(s): Group 2: Golimumab 100 mg + Placebo | Intervention Type: DRUG; Name: Methotrexate capsules; Assigned to Arm(s): Group 1: Placebo + Methotrexate, Group 2: Golimumab 100 mg + Placebo, Group 3: Golimumab 50 mg + Methotrexate, Group 4: Golimumab 100 mg + Methotrexate | Intervention Type: BIOLOGICAL; Name: Golimumab 50 mg injections; Assigned to Arm(s): Group 1: Placebo + Methotrexate, Group 2: Golimumab 100 mg + Placebo, Group 3: Golimumab 50 mg + Methotrexate, Group 4: Golimumab 100 mg + Methotrexate | Intervention Type: BIOLOGICAL; Name: Golimumab 100 mg injections; Assigned to Arm(s): Group 1: Placebo + Methotrexate, Group 2: Golimumab 100 mg + Placebo, Group 3: Golimumab 50 mg + Methotrexate, Group 4: Golimumab 100 mg + Methotrexate
D: Intervention Type: DRUG; Name: CDP870; Assigned to Arm(s): N/A

Answer: C